[vc_row][vc_column][vc_column_text]The provinces of Alberta and Quebec have added pembrolizumab in combination with lenvatinib to their drug formularies for the first-line treatment of adult patients with advanced or metastatic renal cell carcinoma (RCC). Eligible patients should be previously untreated in the metastatic setting and have a good performance status.
Pembrolizumab treatment should continue until confirmed disease progression or unacceptable toxicity to a maximum of 2 years, whichever comes first. Lenvatinib treatment should continue until disease progression or unacceptable toxicity.
[/vc_column_text][vc_empty_space][/vc_column][/vc_row]